News | June 01, 2023
Laurus Labs to increase stake in ImmunoACT to 33.86%
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Testing supporting allergy diagnosis now accessible to more people in more communities
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
From cancer research to diagnostic solutions
Alpenglow has created an end-to-end 3D spatial biology solution including patented high-throughput 3D imaging
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
Subscribe To Our Newsletter & Stay Updated
